Serum stem cell factor levels in patients with aplastic anemia

Stephen D Nimer, D. H Y Leung, M. J. Wolin, D. W. Golde

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Immune suppression of hematopoiesis has been implicated in the pathogenesis of acquired aplastic anemia. Similarly, abnormalities of T cells and bone marrow stromal cells have been reported in aplastic anemia, as has abnormal cytokine production. Stem cell factor (SCE) (also known as kit ligand, mast cell growth factor and Steel factor) is an early acting hematopoietic growth factor that is produced by a variety of mesenchymal cells including bone marrow stromal cells. To determine whether abnormalities in the production of stem cell factor occur in aplastic anemia, we evaluated serum levels of SCF in 25 patients with aplastic anemia. The mean serum levels of SCF in aplastic anemia patients were significantly lower (2.7 ± 1.1 ng/ml) than those found in a comparable population of 257 normal controls (3.3 ± 1.1 ng/ml) (P = 0.011). The SCF level did not correlate with patient age, the duration of aplastic anemia or with white blood cell count, platelet count or hematocrit. Although there is no direct evidence that lower SCF serum levels contribute to the pancytopenia seen in this disorder, identification of underlying abnormalities that can result in the deficient production of stromally derived hematopoietic growth factors will be important.

Original languageEnglish
Pages (from-to)185-189
Number of pages5
JournalInternational Journal of Hematology
Volume60
Issue number3
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Stem Cell Factor
Aplastic Anemia
Serum
Mesenchymal Stromal Cells
Intercellular Signaling Peptides and Proteins
Pancytopenia
Hematopoiesis
Platelet Count
Leukocyte Count
Hematocrit
Cytokines
T-Lymphocytes
Population

Keywords

  • Aplastic anemia
  • Cytokine levels
  • Kit ligand
  • Stem cell factor

ASJC Scopus subject areas

  • Hematology

Cite this

Nimer, S. D., Leung, D. H. Y., Wolin, M. J., & Golde, D. W. (1994). Serum stem cell factor levels in patients with aplastic anemia. International Journal of Hematology, 60(3), 185-189.

Serum stem cell factor levels in patients with aplastic anemia. / Nimer, Stephen D; Leung, D. H Y; Wolin, M. J.; Golde, D. W.

In: International Journal of Hematology, Vol. 60, No. 3, 01.01.1994, p. 185-189.

Research output: Contribution to journalArticle

Nimer, SD, Leung, DHY, Wolin, MJ & Golde, DW 1994, 'Serum stem cell factor levels in patients with aplastic anemia', International Journal of Hematology, vol. 60, no. 3, pp. 185-189.
Nimer, Stephen D ; Leung, D. H Y ; Wolin, M. J. ; Golde, D. W. / Serum stem cell factor levels in patients with aplastic anemia. In: International Journal of Hematology. 1994 ; Vol. 60, No. 3. pp. 185-189.
@article{c87ae61078d24497b9d11b6c931cf4e7,
title = "Serum stem cell factor levels in patients with aplastic anemia",
abstract = "Immune suppression of hematopoiesis has been implicated in the pathogenesis of acquired aplastic anemia. Similarly, abnormalities of T cells and bone marrow stromal cells have been reported in aplastic anemia, as has abnormal cytokine production. Stem cell factor (SCE) (also known as kit ligand, mast cell growth factor and Steel factor) is an early acting hematopoietic growth factor that is produced by a variety of mesenchymal cells including bone marrow stromal cells. To determine whether abnormalities in the production of stem cell factor occur in aplastic anemia, we evaluated serum levels of SCF in 25 patients with aplastic anemia. The mean serum levels of SCF in aplastic anemia patients were significantly lower (2.7 ± 1.1 ng/ml) than those found in a comparable population of 257 normal controls (3.3 ± 1.1 ng/ml) (P = 0.011). The SCF level did not correlate with patient age, the duration of aplastic anemia or with white blood cell count, platelet count or hematocrit. Although there is no direct evidence that lower SCF serum levels contribute to the pancytopenia seen in this disorder, identification of underlying abnormalities that can result in the deficient production of stromally derived hematopoietic growth factors will be important.",
keywords = "Aplastic anemia, Cytokine levels, Kit ligand, Stem cell factor",
author = "Nimer, {Stephen D} and Leung, {D. H Y} and Wolin, {M. J.} and Golde, {D. W.}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "60",
pages = "185--189",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Serum stem cell factor levels in patients with aplastic anemia

AU - Nimer, Stephen D

AU - Leung, D. H Y

AU - Wolin, M. J.

AU - Golde, D. W.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Immune suppression of hematopoiesis has been implicated in the pathogenesis of acquired aplastic anemia. Similarly, abnormalities of T cells and bone marrow stromal cells have been reported in aplastic anemia, as has abnormal cytokine production. Stem cell factor (SCE) (also known as kit ligand, mast cell growth factor and Steel factor) is an early acting hematopoietic growth factor that is produced by a variety of mesenchymal cells including bone marrow stromal cells. To determine whether abnormalities in the production of stem cell factor occur in aplastic anemia, we evaluated serum levels of SCF in 25 patients with aplastic anemia. The mean serum levels of SCF in aplastic anemia patients were significantly lower (2.7 ± 1.1 ng/ml) than those found in a comparable population of 257 normal controls (3.3 ± 1.1 ng/ml) (P = 0.011). The SCF level did not correlate with patient age, the duration of aplastic anemia or with white blood cell count, platelet count or hematocrit. Although there is no direct evidence that lower SCF serum levels contribute to the pancytopenia seen in this disorder, identification of underlying abnormalities that can result in the deficient production of stromally derived hematopoietic growth factors will be important.

AB - Immune suppression of hematopoiesis has been implicated in the pathogenesis of acquired aplastic anemia. Similarly, abnormalities of T cells and bone marrow stromal cells have been reported in aplastic anemia, as has abnormal cytokine production. Stem cell factor (SCE) (also known as kit ligand, mast cell growth factor and Steel factor) is an early acting hematopoietic growth factor that is produced by a variety of mesenchymal cells including bone marrow stromal cells. To determine whether abnormalities in the production of stem cell factor occur in aplastic anemia, we evaluated serum levels of SCF in 25 patients with aplastic anemia. The mean serum levels of SCF in aplastic anemia patients were significantly lower (2.7 ± 1.1 ng/ml) than those found in a comparable population of 257 normal controls (3.3 ± 1.1 ng/ml) (P = 0.011). The SCF level did not correlate with patient age, the duration of aplastic anemia or with white blood cell count, platelet count or hematocrit. Although there is no direct evidence that lower SCF serum levels contribute to the pancytopenia seen in this disorder, identification of underlying abnormalities that can result in the deficient production of stromally derived hematopoietic growth factors will be important.

KW - Aplastic anemia

KW - Cytokine levels

KW - Kit ligand

KW - Stem cell factor

UR - http://www.scopus.com/inward/record.url?scp=0027949253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027949253&partnerID=8YFLogxK

M3 - Article

C2 - 7532030

AN - SCOPUS:0027949253

VL - 60

SP - 185

EP - 189

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -